Dorzolam

Quick links to important sections

Dorzolam

Treatment option: Hypertension, Glaucoma

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dorzolam

Quick Facts

Property Description
Active ingredient Dorzolamide hydrochloride
Form Ophthalmic solution (eye drops)
Pharmacological class Carbonic Anhydrase Inhibitor (CAI)
Common purpose Reduction of intraocular pressure (IOP)
Origin Synthetic compound, Sulfonamide derivative

What Type of Medicine is Dorzolam?

Dorzolam is a prescription-only medication featuring the active ingredient Dorzolamide hydrochloride, which belongs to the topical Carbonic Anhydrase Inhibitor (CAI) pharmacological class. This classification is clinically recognized for its role in altering fluid dynamics within the eye. Dorzolamide is chemically recognized as a synthetic compound derived from the sulfonamide chemical group. This non-antibiotic derivative utilizes a targeted structure to focus its effect primarily on the ocular area. Other recognized brands containing this same active ingredient include Trusopt.

Composition and Form of Dorzolam Eye Drops

The medicine is supplied exclusively as a sterile, aqueous ophthalmic solution (eye drops), intended for topical ophthalmic administration only. The formulation is a single-entity product containing Dorzolamide hydrochloride dissolved within a buffered aqueous vehicle. This composition is essential because it allows for direct application to the eye's surface, which is a key differentiating feature compared to systemic (oral) medications used for related purposes. The specific solution formulation is designed to be well-tolerated while ensuring that the active ingredient is available for its localized action.

How Does Dorzolamide Generally Help?

The core therapeutic purpose of Dorzolamide is to serve as an ocular hypotensive agent, meaning its primary function is the systematic reduction of intraocular pressure (IOP). Dorzolamide achieves this effect by inhibiting the carbonic anhydrase enzyme, which is crucial for the formation and secretion of aqueous humor. This medicine helps by actively slowing the rate of fluid production, a typical use scenario when managing conditions where sustained elevated eye pressure is present. This action supports the regulation of the pressure balance necessary for maintaining overall ocular health.

What side effects are possible with Dorzolam?

Possible Side Effects and Safety Information

The safety profile for Dorzolamide (Dorzolam) is defined by its potential for localized ocular reactions and systemic effects related to its sulfonamide chemical class, as documented in official regulatory labeling.

Frequency-Classified Adverse Reactions

The most frequently reported events are related to the site of application and its taste profile, classified by regulatory authorities as follows:

Frequency Classification Associated Adverse Reactions (Examples)
Very Common Ocular burning, stinging, or discomfort (often immediate); Bitter taste (dysgeusia).
Common Superficial punctate keratitis; Signs of ocular allergic reaction (e.g., lid reactions, conjunctivitis); Blurred vision; Eye redness.
Rare Iridocyclitis (eye inflammation); Urolithiasis (kidney stones); Skin rashes.

System-Organ Classes and Serious Risks

Adverse reactions are formally grouped by the body system affected, including Eye Disorders, Gastrointestinal Disorders, Renal and Urinary Disorders, and Skin and Subcutaneous Tissue Disorders.

Due to systemic absorption, the topical solution carries the potential for rare, serious, system-wide adverse events associated with systemic sulfonamides. These reactions have included, though rarely, fatalities related to Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Agranulocytosis, and Aplastic Anemia, as noted in official safety documentation.

Population-Specific Safety Considerations

The medicine has not been adequately studied in certain patient groups. Caution is recommended in patients with severe renal impairment (Creatinine Clearance <30 mL/min) and in those with hepatic impairment. Safety and efficacy have not been established in children younger than two years of age.

Local adverse effects, such as conjunctivitis and lid reactions, have been reported with chronic administration of the eye drops, while burning and stinging typically occur immediately following administration.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose manifestations and mandated actions for Dorzolam (Dorzolamide hydrochloride), based strictly on government regulatory documents.

Documented Overdose Manifestations

Limited information is available for human overdose following accidental or deliberate ingestion. Manifestations reported from post-marketing experience with both oral and topical exposure include:

Following Oral Ingestion Following Topical/Oral Exposure
Somnolence (drowsiness) Nausea, Dizziness, Headache
Fatigue, Abnormal dreams, Dysphagia

Severe Outcomes and Required Actions

An overdose is associated with the potential for systemic effects related to its pharmacological class, the Carbonic Anhydrase Inhibitor (CAI). Regulatory authorities document the risk of potential complications, including electrolyte imbalance and the development of an acidotic state (metabolic acidosis).

Urgent Medical Help is Required: Due to these serious potential outcomes, treatment must be initiated promptly. Management is defined as symptomatic and supportive. There is no specific antidote documented in official prescribing information.

Monitoring Requirements: Medical supervision is necessary to monitor for systemic effects. Required procedures include the monitoring of serum electrolyte levels (specifically potassium) and blood pH levels to manage potential acid-base imbalance.

Therapeutic Uses of Dorzolam

Quick Facts: Dorzolam Use

Condition Therapeutic Domain
Ocular Hypertension Helps reduce intraocular pressure (IOP)
Open-Angle Glaucoma Manages elevated fluid pressure in the eye

Dorzolam is a medication indicated to help manage elevated intraocular pressure (IOP) in patients with specific eye conditions. Its main therapeutic use is focused on ocular hypertension, a condition characterized by high pressure inside the eye, and open-angle glaucoma. Elevated IOP is a notable risk factor for potential optic nerve damage and subsequent vision changes.

Dorzolam may be used as a monotherapy or in combination with other topical treatments for the purpose of controlling eye pressure. By assisting in the reduction of this elevated pressure, the medication works to maintain the overall health of the eye. It is important to note that Dorzolam is used to control the condition and is not a cure. Patients are advised to continue use as professionally recommended.

Eligibility and Restrictions for Use

Dorzolam (Dorzolamide hydrochloride) is an ophthalmic solution whose official eligibility is defined by the patient’s age, organ health, and sensitivity to the drug’s chemical class, as outlined by regulatory authorities.

Populations that Must Not Use Dorzolam (Contraindications)

Contraindication Basis for Restriction
Known Hypersensitivity Allergy to dorzolamide, the formulation components, or the sulfonamide chemical group.
Severe Renal Impairment Creatinine clearance less than 30 mL/min (due to predominant renal excretion).
Hyperchloraemic Acidosis Risk of worsening acid-base imbalance due to the systemic absorption of the topical carbonic anhydrase inhibitor.

Conditional or Restricted Use

Use of Dorzolam is not recommended or requires special caution in certain populations, reflecting official limitations documented in regulatory labeling:

  • Hepatic Impairment: Caution is advised, as the medicine has not been studied in patients with liver impairment.
  • Pregnancy and Lactation: Use is not generally recommended; a professional evaluation is required to weigh the medicine's importance against potential risks, as adequate human data are lacking.
  • Pediatric Age: Safety and effectiveness are established for children generally 2 years of age and older. Use is not established in infants younger than two years old.
  • Corneal Health: Patients with existing corneal defects or a history of intraocular surgery should use the medicine with caution due to the documented risk of developing corneal edema.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Dorzolam (Dorzolamide hydrochloride ophthalmic solution), based strictly on regulatory prescribing information.

Pharmacodynamic and Systemic Interaction Risks

The primary interaction concerns relate to the systemic absorption of Dorzolam, which is a sulfonamide derivative and a carbonic anhydrase inhibitor.

Interacting Substance Category Official Regulatory Statement
Oral Carbonic Anhydrase Inhibitors (CAIs) Co-administration is not recommended due to the potential for an additive effect on systemic CAI inhibition.
High-Dose Salicylate Therapy Potential for drug interactions, such as toxicity associated with high-dose salicylate therapy, which may be related to acid-base and electrolyte disturbances.

Administration and Clearance Restrictions

Official regulatory documents detail restrictions concerning local co-administration timing and use in specific populations based on elimination pathway.

  • Other Topical Ophthalmic Products: If Dorzolam is used concurrently with other topical ophthalmic drug products, the products must be administered at least five minutes apart.
  • Severe Renal Impairment: Dorzolam is not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min). This restriction addresses the risk of drug and metabolite accumulation due to the dependence on renal excretion.

No specific interactions are documented in official regulatory sources regarding food, alcohol, or herbal products.

Mechanism of Action

Mechanism of Action: Carbonic Anhydrase Inhibition

Dorzolam (dorzolamide) acts as a selective inhibitor of the enzyme carbonic anhydrase type II (CA-II). This enzyme is highly concentrated within the ciliary processes of the eye, which are responsible for the generation of intraocular fluid. The drug binds to CA-II, inhibiting its ability to catalyze the reversible reaction of carbon dioxide ( CO2) and water ( H2 O) to form bicarbonate ions ( HCO3^-) and protons ( H^+).

This enzymatic interference directly affects the aqueous humor production pathway. The active secretion of bicarbonate ions is an essential component of the osmotic process that drives water into the posterior chamber. By suppressing this critical ion transport step, Dorzolam causes a reduction in the rate of aqueous humor formation. This molecular cascade leads to the resulting system-level physiological consequence of reduced intraocular pressure.

Dosage and Administration Information

How to Use Dorzolam

Dorzolam (dorzolamide 2% ophthalmic solution) is administered exclusively via the topical ophthalmic route, meaning it is applied as eye drops directly into the affected eye(s) to achieve its localized effect. The standard dose is one drop per application, with the frequency determined by the overall treatment plan.


Official Dosing Frequency

Usage Scenario Dosing Schedule
Monotherapy One drop three times daily (t.i.d.)
Adjunctive Therapy One drop two times daily (b.i.d.) (when used with an ophthalmic beta-blocker)

Administration Procedures and Timing

To ensure proper administration and reduce systemic absorption, specific procedural steps are followed. When using Dorzolam concurrently with other topical ophthalmic medications, a minimum waiting period is required; the drugs must be administered at least five minutes or ten minutes apart. After instilling the drop, the procedural recommendation is to apply gentle pressure to the nasolacrimal duct (nasolacrimal occlusion) or close the eyelids for approximately two minutes. Furthermore, soft contact lenses must be removed prior to application and can be reinserted 15 minutes afterward.

Population-Specific Instructions

The medication is not recommended for use in patients with severe renal impairment, defined as a creatinine clearance (CrCl) less than 30 mL/min, as the drug and its metabolite are primarily cleared through the kidneys. Caution is also advised when administering Dorzolam to patients with hepatic impairment, as clinical data in this group are limited. The dosing regimen for pediatric patients with elevated intraocular pressure is typically one drop three times daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action

Studies were conducted to investigate the biological activity of the substance. Researchers have explored the biological process by which the substance may produce an effect. Studies continue to investigate the relevant biological processes.

Clinical Trial Findings

Studies have evaluated the combination of drug X with standard therapy, comparing the outcomes to standard therapy alone in a cohort of participants with chronic back discomfort. The clinical trials focused on measuring changes in participant-reported discomfort scores over a period of 12 weeks. Research has examined the substance's effect on markers of discomfort and on functional capacity.

Efficacy and Symptom Management

Research has explored whether the substance was associated with changes in discomfort and inflammation levels. The initial 12-week study phase indicated specific outcomes in a population of participants with non-malignant chronic discomfort. Follow-up research tracked participants for a period of six months to evaluate long-term observations.

The primary studies assessed participant-reported discomfort scores using the Visual Analog Scale (VAS) and evaluated changes in physical function as a secondary measure. Studies included an assessment of patient quality of life as a measured endpoint.

Safety Profile and Adverse Events

Clinical trials and observational studies reported on the incidence of adverse effects and were often conducted with participants who did not have condition X. Common adverse events noted in the research included mild gastrointestinal upset and temporary fatigue. These studies were conducted under the supervision of medical professionals, with participants receiving regular monitoring. Data collection continues in ongoing studies to further describe observed effects.

Ongoing Research

Current research is investigating the substance for use in specific, severe discomfort syndromes, and is examining potential interactions with other common medications. Ongoing research continues to investigate its potential applications. These studies aim to collect more data on long-term observed effects and to refine dosage strategies used in a research setting.

Key Studies & References Clinical Practice Guideline for the Management of Chronic Musculoskeletal Pain (Relevant Section on Combination Therapy)

Frequently Asked Questions (FAQ)

Common questions about Dorzolam (FAQ)


Q: How quickly do the effects of Dorzolam usually start?

A: According to official product information, the maximum effect of lowering the pressure in the eye is typically seen about two hours after the eye drops are applied. This indicates the point at which the concentration is highest for lowering pressure in the eye.


Q: Can I use other eye drops at the same time as Dorzolam?

A: Official guidance advises that if Dorzolam is to be administered with any other topical ophthalmic drug products, the applications should be separated. The medications are generally advised to be administered at least five minutes apart as a recommended practice for administration.


Q: Is a burning sensation in the eye a common side effect when starting Dorzolam?

A: Yes, official regulatory labeling lists ocular burning, stinging, or discomfort as a very common adverse reaction. This sensation typically occurs immediately following the application of the eye drops. Reports indicate it is usually temporary.


Q: What should I do if the Dorzolam drops irritate my eyes significantly?

A: Official patient information states that if a patient develops any significant or unusual eye reactions, particularly signs like allergic conjunctivitis or severe eyelid reactions, discontinuation of use and seeking a medical professional's advice are the steps outlined for patients.


Q: What if I miss using a dose of Dorzolam?

A: Official patient leaflets describe that the missed dose should be skipped if it is almost time for your next scheduled application. Furthermore, official patient information states that a double dose should not be used to make up for a missed dose.


Q: Is there a specific way to apply Dorzolam to ensure it works correctly?

A: Official procedural guidance advises patients to be careful to avoid allowing the tip of the container to touch the eye or surrounding areas. This precaution is intended to help prevent contamination of the solution.


Q: Is Dorzolam safe for people with sulfa allergies?

A: Official documents state that Dorzolam is a sulfonamide derivative and is contraindicated, meaning it must not be used, if a patient has a known hypersensitivity or allergy to the active ingredient or the sulfonamide chemical group.


Q: Are there generic versions of Dorzolam available?

A: The active ingredient, dorzolamide hydrochloride, is available under multiple formulations and brand names. This includes generic products, as well as other branded versions such as Trusopt.


Q: Are there any foods or drinks I should avoid while using Dorzolam?

A: Official regulatory sources state that no specific drug interaction studies have been conducted with food or alcohol while using Dorzolam. The core product label generally does not list any mandatory dietary restrictions.


Q: Does Dorzolam affect other health conditions like asthma or kidney issues?

A: The medicine is not recommended for patients who have severe renal impairment (significant kidney issues). This restriction is in place because the drug is primarily cleared from the body through the kidneys.


Q: Can Dorzolam be used long-term for pressure management?

A: Clinical studies have followed some patients for at least three years, and the pressure-lowering effect was observed to be consistent in studies lasting up to one year. This indicates that continuous, long-term use is a standard scenario for this prescription.


Q: What do official documents say about Dorzolam use in children?

A: Safety and effectiveness for this medication have been officially established in children two years of age and older. The typical pediatric dosing regimen is one drop three times daily. Use in infants under two years old has not been established.


Q: Will using Dorzolam affect how I drive or operate machinery?

A: Since the medication can cause side effects such as temporary blurred vision and dizziness, regulatory documents advise that patients should be cautious when driving or operating machines if these effects occur.


Q: Is the red eye I experience related to Dorzolam use?

A: Yes, eye redness (conjunctival hyperaemia) is listed in official documents as a common adverse reaction associated with the use of the eye drops. If this symptom is severe or persistent, official patient information advises that seeking medical guidance is the recommended course of action.


Q: Can Dorzolam affect blood pressure or heart rate?

A: Dorzolam can be absorbed systemically, and regulatory documents list rare systemic adverse reactions related to this. These have included, though rarely, events such as chest pain, palpitations, and arrhythmia (irregular heart rhythm).


Q: Is there a limit to how long someone can use Dorzolam?

A: There is no officially specified maximum duration of use. Clinical studies have followed some patients for at least three years, suggesting continuous use is common when prescribed for long-term pressure management.


Q: What if Dorzolam is accidentally swallowed?

A: In the event of accidental oral ingestion of the solution, official safety data sheets advise immediately seeking medical advice. Patients are advised to only rinse the mouth with water and not attempt to induce vomiting.


Q: Does Dorzolam contain preservatives?

A: Multidose bottles of Dorzolam typically contain benzalkonium chloride as a preservative to maintain sterility over time. However, preservative-free formulations are also available in single-dose containers.


Q: Do people with dry eyes tolerate Dorzolam well?

A: Official regulatory warnings advise caution in patients with existing corneal defects due to a potential risk of developing corneal swelling (edema). Dry eyes are also listed as a less common reported side effect, suggesting a potential for interaction with the tear film.


Q: How does Dorzolam affect tear production?

A: While the primary effect is to reduce fluid formation inside the eye, official side effect listings from clinical trials have included reports of increased tearing (lacrimation). This is not the primary known effect on the tear film.


Q: Does using Dorzolam change the size of the pupil?

A: Clinical research has examined this effect and reported a slight decrease in pupil size with the use of Dorzolam. However, this change is generally not considered to be clinically significant.


Q: Are there restrictions on using Dorzolam before or after eye surgery?

A: Official patient information advises that if a patient is scheduled for ocular surgery or develops any new eye condition (such as trauma or infection), seeking advice from a physician regarding the continued use of the multi-dose container is the appropriate step.


Q: Can older adults use Dorzolam safely?

A: Official information regarding use in geriatric patients (older adults) indicates that clinical trials did not find an overall difference in effectiveness or safety between older and younger patients. Dosage adjustment is generally not required for the elderly.


Q: Does Dorzolam have any known interactions with herbal supplements?

A: Official regulatory sources state that no specific drug interaction studies have been conducted with herbal products. This means that there are no known, officially documented interactions between Dorzolam and herbal supplements.


Q: Why is Dorzolam only for use in the eyes?

A: The medicine is specifically formulated as an ophthalmic solution for topical use to target the pressure-regulating enzyme carbonic anhydrase in the eye. This targeted delivery is intended to maximize its effect on fluid reduction within the eye while limiting widespread systemic effects.


Q: Does the time of day matter when using Dorzolam?

A: Official patient information suggests that using the drops at the same time each day (for example, once in the morning and once in the evening for twice-daily dosing) helps to ensure the most consistent pressure-lowering effect.


How should Dorzolam be stored and disposed of?

Official Storage and Disposal Instructions

Storage Conditions and Handling

The Dorzolam ophthalmic solution must be stored at controlled room temperature, generally defined as between 15 C and 30 C (59 F and 86 F). To maintain the product's integrity, it is mandatory to keep the medicine from freezing. The container must be kept tightly closed when not in use, and the product should be stored away from excess heat, moisture, and protected from direct light.

Stability and Discard Rules

Container Type Post-Opening Stability Rule
Multi-Dose Bottle Discard within 28 days of first opening (or as specified on the label).
Single-Dose Container Discard immediately after use in the affected eye(s) due to sterility concerns.

Safety and Disposal Requirements

Keep Dorzolam and all medicines out of the sight and reach of children. Any outdated or unused medicine must be disposed of in accordance with local requirements and pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dorzolam found in:

A-Z Index: